NCVI

The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), launched in December 2023, has a unique mission to harness airway immunity through innovative vaccine research and development to prevent airborne epidemics.  NIVI has two parts:

• NIVI Research (NIVI-R): A cutting-edge research center anchored to the University of Copenhagen.
• NIVI Development (NIVI-D): A company that focuses on translational sciences and advancing vaccine development.

NIVI-R conducts scientific research, while NIVI-D works to quickly turn that research into new vaccine candidates. NIVI-D accelerates clinical trials (phases 1 and 2) and ensures a smooth transition to partners for later stages of development.

By connecting science, innovation, clinical trials, regulatory processes, and product development, NIVI aims to streamline the journey from research to real-world vaccines.